1. The rare autosomal-recessive Berardinelli-Seip congenital lipodystrophy syndrome (BSCL) is characterized by general lipodystrophy, acromegalic appearance, hypertriglyceridemia, insulin resistance and hepatomegaly.

2. Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy

3. As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption

4. Localized Atrophy of adipose tissue— lipodystrophy—may be the result of injury to the local area; e.g., repeated insulin injections cause Atrophy of fatty tissue at the site of the injections

5. The HIV lipodystrophy syndrome, a condition characterized by subcutaneous fat loss sometimes associated with relative or absolute accumulation of central fat, has a high prevalence in the treatment of HIV infection.

6. Pharmaceutical preparations, namely pharmaceutical preparations for the treatment and prevention of lipoatrophy, lipodystrophy, hypothalamic amenorrhea, leptin deficiency, metabolic disorders, endocrine conditions and disorders, diabetes, hepatomegaly, hormonal diseases and disorders, obesity, eating disorders, gastrointestinal disorders, immunological disorders, inflammation and inflammatory diseases, neurological disorders, psychiatric disorders, pain, peripheral nervous system diseases and disorders, reproductive disorders, sexual dysfunction, urological disorders